Share This Page
Drugs in ATC Class G01AX
✉ Email this page to a colleague
Drugs in ATC Class: G01AX - Other antiinfectives and antiseptics
| Tradename | Generic Name |
|---|---|
| FUROXONE | furazolidone |
| BETADINE | povidone-iodine |
| E-Z PREP | povidone-iodine |
| POVIDONE IODINE | povidone-iodine |
| E-Z PREP 220 | povidone-iodine |
| >Tradename | >Generic Name |
ecutive summary: ATC G01AX (Other antiinfectives and antiseptics, gynecologic use) is a fragmented category with product-level patent estates that drive market exclusivity more than any single “category” IP block. Competitive pressure typically comes from (1) new chemical entity cycles in narrow indications (e.g., candidiasis-related products), (2) formulation and delivery patents (e.g., gels, creams, suppositories, combinations), and (3) incremental manufacturing/process protection. The category’s patent dynamics are most sensitive to local FDA labeling and exclusivity design (e.g., NDA exclusivity, patent-term adjustment) and to Orange Book listing granularity, which varies by product and dosage form.
What patents protect ATC G01AX other antiinfectives and antiseptics products?
ATC G01AX spans “other” antiinfectives and antiseptics used intravaginally or related gynecologic contexts. Patent protection is usually product-specific and clusters into three groups:
- Active ingredient or stereoisomer coverage (rarely broad at the category level in “other” buckets).
- Formulation and dosage-form patents (common, especially for hydrogels, mucoadhesive gels, controlled-release systems, and combination products).
- Method-of-use patents (common for dosing regimens, patient subgroups, and maintenance or prophylaxis claims).
Which patent families dominate G01AX?
In practice, the dominant IP levers for “other” gynecologic antiinfectives and antiseptics tend to be:
- Formulation/process patents: excipient systems, pH buffers, viscosity targets, stability under storage, and package compatibility.
- Device or delivery integration: applicators, intravaginal administration systems, and controlled-release performance claims.
- Combination therapy claims: co-administration of an antiseptic with an antifungal/antibacterial component, including fixed-dose ratios and schedule.
How many patents cover typical G01AX products?
Coverage volume is product-dependent, but estates often look like:
- 1–3 primary composition-of-matter families
- 2–6 formulation families
- 1–4 process/manufacturing families
- 0–6 method-of-use or regimen families This yields a typical “Orange Book footprint” of a few to dozens of patents, with independent coverage tied closely to whether a patent is listed for a specific strength and dosage form.
When do ATC G01AX products lose exclusivity and what timelines matter for generic entry?
Exclusivity timing for G01AX depends on whether the product is:
- a small-molecule NDA,
- an OTC/legacy product with limited modern exclusivity, or
- a product with new formulation that resets FDA exclusivity only if it is an NDA with qualifying exclusivity.
Exclusivity timeline mechanics that drive entry risk
For FDA-regulated intravaginal products, the critical dates are:
- NDA approval date (governs some non-patent exclusivities),
- listed patent expiration dates in the Orange Book,
- patent-term adjustment (PTA) effects on listed patents,
- patent-term extensions (PTE) when applicable (less common in many antiseptic/antiinfective categories),
- and Any granted exclusivity for pediatric, orphan, or new clinical studies when tied to the active moiety.
What matters for “generic launch scenarios”
Generic entry risk typically accelerates when:
- the last listed patent expires for the exact dosage form/strength,
- and any active 90-day filing window (Paragraph IV) aligns with a realistic ability to launch at or shortly after expiration.
What is the Orange Book status of ATC G01AX products and how many patents are listed?
Orange Book status varies widely by product. For meaningful market dynamics, the number and type of listed patents must be checked product-by-product because:
- formulation-only patents are frequently listed,
- some method-of-use patents may be listed for only certain strengths,
- and combination products can have separate patent coverage layers.
Patent listing pattern that changes competitive outcomes
Across “other antiseptics,” a common pattern is:
- a small set of early composition-of-matter patents (often already expired),
- followed by multiple later-expiring formulation/manufacturing patents that keep the FDA-approved product protected even after API freedom-to-operate improves.
Which companies are challenging G01AX patents via Paragraph IV and what litigation patterns apply?
Paragraph IV activity for G01AX tends to be scattered across individual actives and formulations, with challenges usually focused on:
- formulation and process patents (where equivalency can be argued),
- or method-of-use regimen patents (where labeling carve-outs are often used).
Typical litigation posture in G01AX
When challenges occur, settlement and launch timing often reflect:
- carve-out labeling that avoids infringement of method-of-use claims,
- approval dates tied to when a specific listed patent expires or when a settlement permits launch.
What formulation patents protect intravaginal gels, creams, and suppositories in G01AX?
Formulation is the central battleground in many G01AX estates. Claims often cover:
- pH ranges and buffering systems (to stabilize active antiseptics/antimicrobials),
- viscosity/mucoadhesive excipient profiles to improve residence time,
- stability and shelf-life targets under temperature and packaging conditions,
- release kinetics for controlled-release systems,
- and particle size/dispersion when relevant.
How does formulation IP affect manufacturing/IP barriers?
Even if a generic can match API and strength, manufacturing can be blocked by:
- excipient composition claims,
- sterility/aseptic or fill-finish process claims,
- packaging compatibility claims.
Those barriers are less about “chemical similarity” and more about the ability to design around a claim without losing product performance and stability.
What method-of-use patents for G01AX impact labeling and generic carve-outs?
Method-of-use patents in intravaginal antiinfectives and antiseptics typically claim:
- dosing frequency (once daily vs multi-day regimens),
- duration and treatment windows,
- maintenance or prevention regimens after initial cure,
- patient subgroup dosing (e.g., recurrent infections, specific disease severity categories).
How do generic carve-outs work in practice?
When a generic is at risk under method-of-use claims, the usual market outcome is:
- labeling adjustments that omit the protected regimen,
- with continuing competition on the non-protected indication or schedule.
This reduces infringement risk but can narrow generic uptake.
How does biosimilar risk apply to ATC G01AX?
Biosimilar risk is generally low for G01AX because the category is dominated by small-molecule antiseptics and antiinfectives, not biologics. If a product is derived from biologic sources or uses biologic antimicrobials, then biosimilar frameworks could matter, but the category classification suggests small-molecule predominance.
How strong is the patent estate for G01AX products and what drives strength?
“Strength” in G01AX is less about claim breadth and more about:
- number of Orange Book patents tied to the product,
- later-expiring formulation/manufacturing patents,
- and whether the estate includes multiple independent claim types (composition + formulation + process).
Key strength indicators used in competitive strategy
- Later expiration of formulation/process patents (keeps shelf-protected product competitive longer).
- Multiple patents covering different potential design-arounds (reduces generic engineering flexibility).
- History of settlements (signals litigation cost and probability of a negotiated launch).
- Dependence on narrow excipient compositions (often easier to design around but can be hard if performance is tied to the specific excipient system).
What regulatory and exclusivity constraints apply to G01AX products in the US?
For intravaginal antiinfectives and antiseptics, regulatory constraints that influence exclusivity and launch include:
- whether the product is NDA vs ANDA,
- whether the active ingredient is already generic/compendial,
- and whether the product is positioned as new formulation with new clinical data.
FDA pathway effects
- If the originator has a tightly protected NDA with robust formulation patents, ANDA sponsors may target Paragraph IV against listed patents.
- If the originator relies heavily on formulation patents, ANDA sponsors often either:
- design around excipient/process claims and seek non-infringing approval, or
- negotiate settlement-based entry.
How does ATC G01AX compare with adjacent gynecologic antiseptic categories (e.g., D01, G01B) on patent pressure?
Patent pressure typically shifts by category because:
- other gynecologic antifungals (often in D01) may have more cohesive active ingredient patent lineages,
- antiseptics and “other antiinfectives” (G01AX) usually show more formulation and regimen patchwork.
The result is that G01AX tends to produce more localized “product-level” exclusivity outcomes, with fewer category-wide tailwinds.
Market dynamics: pricing, supply, and switching drivers in G01AX
Even with patent protection, market performance depends on:
- tolerability and local tolerability perceptions (drives switching),
- ease of administration (applicators, dosing convenience),
- clinical positioning (treatment vs prevention vs recurrent infection strategies),
- payer coverage decisions for intravaginal regimens,
- and competitive product availability at the time of generic entry.
What changes after exclusivity expiry
After patent or exclusivity expiry, competition can accelerate through:
- ANDA launches with close excipient/performance matching,
- retailer/institution switching based on price,
- and reformulations by incumbents to extend product differentiation through non-infringing new versions.
Key Takeaways
- ATC G01AX market exclusivity is driven by product-specific Orange Book-linked patent estates, especially formulation and method-of-use protections.
- Competitive entry timing depends on the exact dosage form/strength patent list, not on category assumptions.
- Patent strength in G01AX is strongest where estates combine later-expiring formulation/process patents with multiple independent claim types, limiting generic design-around options.
- Paragraph IV challenges, when they occur, usually target formulation/process or method-of-use claims, with settlements often translating into label carve-outs and negotiated launch dates.
- Post-expiry market share gains are shaped by switching drivers like dosing convenience, tolerability, and payer coverage, not by API equivalence alone.
FAQs
- What types of patents most often stay listed longest for intravaginal antiseptics under ATC G01AX?
- How do Orange Book patent expirations differ across strengths and dosage forms within the same G01AX product?
- What Paragraph IV litigation outcomes most frequently lead to early generic entry for gynecologic antiinfectives?
- How do method-of-use patents influence generic labeling and treatment regimen scope for G01AX products?
- When incumbents launch reformulated intravaginal versions in G01AX, what patent strategies commonly reset exclusivity?
References (APA)
- FDA. (n.d.). Drugs@FDA. U.S. Food and Drug Administration.
- FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
More… ↓
